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Figure 1. Trametinib suppresses GVHD in the BDF1 model
Figure 3. Trametinib spares GVT effects
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versus-Tumor (GVT) effects are spared.
Methods: We adopted three murine BMT models: 1)
Transplantation of B6-BM and T cells into B6D2F1 mice
(MHC-haploidentical BDF1 model); 2) Transplantation of
B10.D2-BM and T cells into Balb/c mice (Skin GVHD and
immune alopecia model); 3) Transfusion of P815 cells in the
BDF1model (GVTmodel). Various doses of the MEK inhibitor
trametinib (or vehicle) were orally given.
Results: 15-days administration of trametinib signiﬁcantly
prolonged survival of GVHD mice (Fig. 1), and suppressed
GVHD symptoms and pathology in the gut and skin. BDF1-
GVHD mice revealed increased phosphorylation of ERK in
peripheral blood CD4 and CD8 T cells, which was suppressed
by trametinib (Fig. 2). Trametinib also suppressed expansion
and functional differentiation of donor T cells in vivo.
Although high-dose trametinib (1.0 mg/kg/day) exerted
toxicity, low-dose trametinib (0.1-0.3 mg/kg/day) was toler-
able while still suppressing GVHD. Notably, in the GVT
model, trametinib did not shorten survival of P815- and T
cell-transplanted mice, indicating that it does not suppressFigure 2. Peripheral blood T cells of BDF1-GVHD mice show increaseGVT effects (Fig. 3). Furthermore, trametinib therapy did not
interfere with engraftment nor expansion of Foxp3+ regula-
tory T cells (data not shown).
Conclusions: These results conﬁrmed that trametinib
selectively suppresses GVHD-inducing T cells while sparing
tumor-speciﬁc T cells and other cell subsets in vivo. Given the
demonstrated safety of trametinib in clinical trials of mela-
noma, MEK inhibition may be a promising candidate for
translational studies aimed at preventing or treating GVHD
after allogeneic transplantation.
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Introduction: High-dose, post-transplantation cyclophos-
phamide (PTCy) is effective as single-agent graft-versus-host
disease (GVHD) prophylaxis after myeloablative conditioning
(MAC) and human leukocyte antigen (HLA)-matched-related
or -unrelated allogeneic bone marrow transplantation
(alloBMT), producing grade III-IV acute GVHD and chronic
GVHD rates of approximately 10-15% each. However, it is
unknown whether plasma-derived proteomic biomarkers
previously established using other transplantation platforms
are applicable to PTCy-treated patients.
Methods: Plasma was obtained from the peripheral blood of
100 adult patients, 70 of whom received busulfan/ﬂudar-
abine MAC and 30 of whom received busulfan/cyclophos-
phamide MAC, at month 1 and month 2-3 post-transplant.
Twelve healthy controls were used as a comparative group.
Plasma was analyzed using ELISA for interleukin-2 receptor
alpha (IL-2ra), IL-6, tumor necrosis factor receptor-1 (TNFR-
1), elaﬁn, regenerating islet-derived 3-alpha (REG3a), sup-
pression of tumorigenicity 2 (ST2), and chemokine (C-X-C
motif) ligand 9 (CXCL9).
Results: Plasma levels of 6 of the 7 putative biomarkers were
signiﬁcantly elevated (p<0.0001) in patients at 1 month
post-transplant compared with healthy controls; only elaﬁn
levels were similar between patients and controls. Plasma
levels of IL-2ra (p¼0.038), CXCL9 (p¼0.0003), and IL-6
(p¼0.032) at 1 month post-transplant were elevated in pa-
tients who would subsequently develop grade II-IV acute
GVHD. There also was a tendency of a relationship (p¼0.06)
between elevated elaﬁn levels at 1 month post-transplant
and grade II-IV acute GVHD development. None of the 7
biomarkers at post-transplant month 1 was prognostic of
chronic GVHD development. However, elevated REG3a levels
at month 2-3 were prognostic of the subsequent develop-
ment of chronic GVHD (p¼0.027). Elevations in 4 of the 7
biomarkers (IL-2ra, p¼0.014; IL-6, p¼0.024; TNFR-1,
p¼0.033; and ST-2, p¼0.0032) were predictive of non-
relapsemortality (NRM). Levels of the 7 biomarkers atmonth
1 were not predictive of permanent cessation of immuno-
suppressive therapy for GVHD by 1 year post-transplant.
Conclusion: Levels of all 7 tested biomarkers at month 1 or
month 2-3 post-transplant were prognostic for the occur-
rence of acute GVHD, chronic GVHD, and/or NRM in patients
treated with PTCy as single-agent GVHD prophylaxis after
MAC and HLA-matched-related or -unrelated alloBMT.
Testing of these biomarkers at earlier post-transplant time
periods or at patient-speciﬁc time points such as initiation of
treatment for GVHD may have added clinical utility in the
care of PTCy-treated patients.487
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The leukocyte adhesion molecule DNAM-1, also known as
CD226, is constitutively expressed of most CD4+ T cells, CD8+
T cells and natural killer (NK) cells. The poliovirus receptor
CD155, which is expressed on both hematopoietic and non-
hematopoietic cells, is a ligand for DNAM-1 and TIGIT. Upon
ligand binding, DNAM-1 mediates an activating signal in T
cells and NK cells. TIGIT acts as a marker for regulatory T cell
(Treg) subset and contributes to the Treg-mediated sup-
pression. We have recently demonstrated a critical role of
DNAM-1 on donor T cells in the development of acute GVHD
in a mouse model (Nabekura, et al, PNAS, 2010, 2011). Recent
reports also showed that DNAM-1 on donor cells promoted
acute GVHD in a CD4+ T cell-dependent manner via the in-
hibition of donor Treg expansion. Here, we found total body
irradiation upregulated CD155 expression on recipient’s
dendritic cell. Therefore, we examined the role of CD155
expressed on host cells in the development of acute GVHD by
using CD155-deﬁcient mice.
Lethally irradiated CB6F1 wild type (WT) or Cd155-/- mice
were transplanted with 5 x 106 bone marrow (BM) cells
together with 2 x 106 splenic T cells derived from C57BL/6
mice. Cd155-/- recipient mice showed body weight loss
signiﬁcantly greater than did WT mice after transplantation
(P < 0.05). Furthermore, Cd155-/- mice showed signiﬁcantly
shorter survival than WT mice (P < 0.01). Similar results
were obtained in an acute GVHDmodel (C57BL/6/BALB/c, P
< 0.05). Further analyses revealed that Cd155-/- recipient
mice showed decreased donor-derived Treg cell population,
compared with WT recipient mice (P < 0.01). Depletion of
Treg cells from transplanted splenic T cells resulted in com-
parable body weight loss and mortality between WT and
Cd155-/- recipient mice after transplantation. These results
suggest that host CD155 regulates the number of Treg cells
and attenuated the development of acute GVHD.
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Background: Unrelated cord blood transplantation (UCBT)
has increasingly been performed. Because cord blood units
